© 1999 Oxford University Press
Article |
Phenobarbital promotes liver growth in c-myc/TGF-
transgenic mice by inducing hypertrophy and inhibiting apoptosis
Laboratory of Experimental Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255, USA
Phenobarbital (PB) is a non-genotoxic liver tumor promoter used extensively in initiation–promotion protocols. To determine the mode of PB action, double transgenic mice overexpressing both the c-myc and transforming growth factor (TGF)-
genes were treated with PB in the food for 10 weeks, from 3 weeks of age. After 3–4 weeks on PB a peak in liver mass was noted, which subsequently leveled off at a value ~30% above untreated animals. The mitotic index in mice given PB peaked at 1 week of treatment and was significantly elevated compared with untreated animals. No significant difference between treated and untreated animals was seen thereafter, although a trend of PB-associated mitotic suppression was noticeable. The apoptotic index also showed a trend of suppression compared with untreated animals, significant after prolonged PB administration. Dysplastic hepatocytes were more prominent in PB-treated mice than untreated animals, particularly pericentrally. Removal of PB from the diet at 4 weeks of treatment led to a dramatic increase in apoptosis. This accompanied a drop in the liver mass to the level of untreated controls by 10 days. Throughout the study, PB-treated animals showed markedly lower levels of TGF-ß1 ligand, coincident with an elevated level of the anti-apoptotic protein Bcl-2. On withdrawal of PB, the levels of all these proteins rapidly changed to mirror those seen in untreated mice. In all treatment groups, no change in the levels of epidermal growth factor receptor, TGF-ß receptors I and II or Bcl-xS/L were seen. We conclude from our data that PB stimulates liver growth in double transgenic c-myc/TGF- mice by induction of liver hypertrophy and inhibition of apoptosis, brought about by both a decrease in signaling through the TGF-ß pathway and an increase in Bcl-2. The data support the hypothesis that PB promotes neoplastic development through a reduction in the incidence of cell death.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. F. Calvisi, S. Ladu, V. M. Factor, and S. S. Thorgeirsson Activation of {beta}-catenin provides proliferative and invasive advantages in c-myc/TGF-{alpha} hepatocarcinogenesis promoted by phenobarbital Carcinogenesis, June 1, 2004; 25(6): 901 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. V. Kalinichenko, M. L. Major, X. Wang, V. Petrovic, J. Kuechle, H. M. Yoder, M. B. Dennewitz, B. Shin, A. Datta, P. Raychaudhuri, et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor Genes & Dev., April 1, 2004; 18(7): 830 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kinoshita, H. Wanibuchi, S. Imaoka, M. Ogawa, C. Masuda, K. Morimura, Y. Funae, and S. Fukushima Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21WAF1/Cip1, cyclin D1 and Ogg1 Carcinogenesis, February 1, 2002; 23(2): 341 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yan, Z.-Z. Zeng, S. Higashi, A. Denda, Y. Konishi, S. Onishi, H. Ueno, K. Higashi, and H. Hiai Resistance of DRH strain rats to chemical carcinogenesis of liver: genetic analysis of later progression stage Carcinogenesis, January 1, 2002; 23(1): 189 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Calvisi, V. M. Factor, R. Loi, and S. S. Thorgeirsson Activation of {beta}-Catenin during Hepatocarcinogenesis in Transgenic Mouse Models: Relationship to Phenotype and Tumor Grade Cancer Res., March 1, 2001; 61(5): 2085 - 2091. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Yoshinari, T. Sueyoshi, R. Moore, and M. Negishi Nuclear Receptor CAR as a Regulatory Factor for the Sexually Dimorphic Induction of CYP2B1 Gene by Phenobarbital in Rat Livers Mol. Pharmacol., February 1, 2001; 59(2): 278 - 284. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Christensen, E. H. Romach, L. N. Healy, A. J. Gonzales, S. P. Anderson, D. E. Malarkey, J. C. Corton, T. R. Fox, R. C. Cattley, and T. L. Goldsworthy Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice Carcinogenesis, August 1, 1999; 20(8): 1583 - 1590. [Abstract] [Full Text] [PDF]
|
|